Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;8(4):261-6.
doi: 10.1177/1758834016644156. Epub 2016 Apr 25.

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Romualdo Barroso-Sousa  1 , Otto Metzger-Filho  2
Affiliations
Review

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Romualdo Barroso-Sousa et al. Ther Adv Med Oncol. 2016 Jul.

Abstract

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC): ILC differs from invasive ductal carcinoma (IDC) in its clinicopathological characteristics and responsiveness to systemic therapy. From the clinical standpoint, data suggest that ILC derives a distinct benefit from systemic therapy compared to IDC. In addition, comprehensive molecular analyses have been reported for ILCs, confirming that these tumors have specific genomic profiles compared to IDC. Despite these differences, clinical trials and practical clinical guidelines tend to treat BC as a single entity. Here we discuss these clinical and molecular data and their therapeutic implications.

Keywords: TCGA; breast neoplasm; chemotherapy; invasive ductal carcinoma; invasive lobular carcinoma; letrozole; tamoxifen; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared that there is no conflict of interest.

References

    1. Bomeisl P., Thompson C., Harris L., Gilmore H. (2015) Comparison of Oncotype Dx recurrence score by histologic types of breast carcinoma. Arch Pathol Lab Med 139: 1546–1549. - PubMed
    1. Carroll J., Liu X., Brodsky A., Li W., Meyer C., Szary A., et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FOXA1. Cell 122: 33–43. - PubMed
    1. Ciriello G., Gatza M., Beck A., King T., Perou C., Ciriello G., et al. (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163: 506–519. - PMC - PubMed
    1. Conlon N., Ross D., Howard J., Catalano J., Dickler M., Tan L. (2015) Is there a role for Oncotype Dx testing in invasive lobular carcinoma? Breast J 21: 514–519. - PMC - PubMed
    1. Cristofanilli M., Gonzalez-Angulo A., Sneige N., Kau S., Broglio K., Theriault R., et al. (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23: 41–48. - PubMed

LinkOut - more resources